Cite
HARVARD Citation
Evertsson, B. et al. (2020). A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple sclerosis journal, experimental, translational and clinical. 6 (4), p. . [Online].